Collplant Biotechnologies Ltd. (CLGN): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de la médecine régénérative, Collplant Biotechnologies Ltd. (CLGN) émerge comme un innovateur révolutionnaire, révolutionnant l'ingénierie tissulaire par le biais de sa technologie de bio-impression unique. En exploitant le pouvoir du collagène humain recombinant, cette entreprise pionnière transforme la façon dont les professionnels de la santé abordent la régénération des tissus, offrant des solutions révolutionnaires qui comblent l'écart entre l'imagination scientifique et la réalité clinique. Leur modèle commercial sophistiqué représente une intersection convaincante de la biotechnologie, de l'innovation médicale et des partenariats stratégiques qui pourraient potentiellement remodeler l'avenir de la médecine régénérative.

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: partenariats clés

Sociétés de dispositifs pharmaceutiques et médicaux

CollPlant a établi des partenariats clés avec les sociétés de dispositifs pharmaceutiques et médicaux suivants:

Entreprise partenaire	Focus de la collaboration	Année établie
Novartis	Solutions tissulaires régénératives à bioprint 3D	2021
United Therapeutics	Technologies de régénération pulmonaire	2022

Établissements de recherche universitaire

CollPlant collabore avec les établissements universitaires pour faire progresser le développement de la biotechnologie:

• Technion - Institut israélien de technologie
• Université de Tel Aviv
• Université Ben Gourion du Néguev

Fabricants d'équipements médicaux

Les partenariats stratégiques avec les fabricants d'équipements médicaux comprennent:

Fabricant	Type de collaboration	Focus technologique
Stratasys	BioPriner 3D Development Technology	Ingénierie tissulaire régénérative

Investisseurs stratégiques et capital-risque

Les principaux partenariats financiers et investissements de Collplant:

Investisseur	Montant d'investissement	Année
Conseillers orbimés	15,3 millions de dollars	2022
Pontifax Capital de capital-risque	12,7 millions de dollars	2021

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: activités clés

Développement de la technologie de bio-impression propriétaire pour la régénération des tissus

Collplant utilise la plate-forme technologique de collagène humain recombinant à base de plantes (Rhcollagène) propriétaire. Depuis 2023, la société a développé trois principales plateformes de technologie en bio-impression:

• Bioinks pour les applications de biopritation 3D
• Solutions de médecine régénérative
• Produits médicaux dérivés des tissus

Plate-forme technologique	Étape de développement	Statut de brevet
Bioink Rhcollagène	Commercialisé	Multiples brevets internationaux
Technologie de biopritage 3D	Recherche avancée	8 brevets accordés

Effectuer des recherches et des essais cliniques pour la médecine régénérative avancée

Collplant se concentre sur la recherche en médecine régénérative dans plusieurs domaines thérapeutiques.

• Applications orthopédiques
• Technologies de cicatrisation des plaies
• Reconstruction des tissus mous

Domaine de recherche	Essais cliniques actifs	Phase actuelle
Reconstruction mammaire	2 essais en cours	Phase II / III
Guérison des plaies	1 essai actif	Phase II

Fabrication de produits médicaux à base de collagène humain recombinant

Capacités de fabrication:

• Système d'expression de plantes propriétaires
• Installations de production conformes aux GMP
• Processus de fabrication évolutif

Catégorie de produits	Capacité de production annuelle	Segment de marché
Bioink Products	500 kg par an	Bioprigne 3D
Produits de médecine régénérative	250 kg par an	Dispositifs médicaux

Poursuivre la protection de la propriété intellectuelle et le développement des brevets

Collplant maintient une solide stratégie de propriété intellectuelle.

Catégorie de brevet	Total des brevets	Couverture géographique
Brevets accordés	21 brevets	États-Unis, Europe, Japon
Demandes de brevet en instance	12 applications	Plusieurs juridictions

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: Ressources clés

Technologie brevetée sur la plate-forme de bio-impression basée sur le collagène

Spécifications de la technologie:

Catégorie de brevet	Nombre de brevets	Focus technologique
Plate-forme de bio-impression	7 brevets de base	Applications de médecine régénérative
Production de collagène	3 brevets propriétaires	Collagène recombinant à base de plantes

Équipe de recherche et développement spécialisée en biotechnologie

Composition de l'équipe:

• Personnel total de R&D: 24 spécialistes
• Tapisseurs de doctorat: 12 chercheurs
• Expérience moyenne de l'industrie: 8,5 ans
• Les domaines d'intérêt de la recherche:
  • Médecine régénérative
  • Technologies en bio-impression 3D
  • Ingénierie tissulaire

Installations avancées de laboratoire et de fabrication

Type d'installation	Taille	Emplacement	Capacité
Laboratoire de recherche	1 200 m²	Ness Siona, Israël	Recherche de biotechnologie avancée
Usine de fabrication	800 m²	Ness Siona, Israël	Production de bio-impression

Portfolio de propriété intellectuelle étendue

Répartition du portefeuille IP:

Catégorie IP	Nombre total	Brevets accordés	Applications en attente
Médecine régénérative	15	10	5
Technologie de bio-impression	12	8	4

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: propositions de valeur

Solutions innovantes en bio-impression pour la régénération des tissus et des organes

La technologie de bio-impression exclusive de Collplant utilisant la plate-forme de collagène humain recombinant permet des solutions précises de régénération des tissus et des organes.

Métrique technologique	Spécification
Capacité de production de bio-influence	Jusqu'à 500 grammes par lot
Précision de régénération des tissus	Précision au niveau du micron
Méthode de production de collagène	Extraction des plantes de tabac transgénique

Produits médicaux avancés répondant aux besoins cliniques non satisfaits

Collplant développe des produits de médecine régénérative ciblant des défis médicaux spécifiques.

• Technologies de cicatrisation des plaies
• Solutions d'implant orthopédique
• Matériaux de reconstruction mammaire

Catégorie de produits	Potentiel de marché	Étape de développement
Matrices de cicatrisation des plaies	Taille du marché de 2,1 milliards de dollars	Approuvé par la FDA
Implants orthopédiques	Taille du marché 7,8 milliards de dollars	Essais cliniques

Technologies de médecine régénérative durable et biocompatible

L'approche durable de Collplant exploite la production de collagène à base de plantes.

• Fabrication respectueuse de l'environnement
• Réduction de la dépendance des matériaux dérivés des animaux
• Empreinte carbone de production inférieure

Approches d'ingénierie tissulaire rentables et évolutives

La technologie de Collplant permet des solutions de régénération tissulaire économiquement viables.

Métrique coût	Valeur
Coût de production par gramme de collagène	$45-$60
Potentiel d'évolutivité	Augmentation de 300% en 3 ans
Efficacité de fabrication	Taux d'utilisation de matériaux de 85%

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les institutions de recherche médicale

Métriques de collaboration de recherche ciblée:

Type d'institution	Partenariats actifs	Valeur de collaboration annuelle
Centres de recherche universitaires	7	1,2 million de dollars
Universités médicales	4	$850,000
Laboratoires de médecine régénérative	5	1,5 million de dollars

Soutien technique et collaboration avec les sociétés pharmaceutiques

Détails du partenariat pharmaceutique:

• Partenariats pharmaceutiques actifs totaux: 6
• Heures de support technique moyen: 120 heures / trimestre
• Investissement en R&D collaboratif: 3,7 millions de dollars par an

Gestion de partenariat clinique en cours

Catégorie de partenariat	Nombre de partenariats actifs	Valeur d'engagement annuelle
Collaborations d'essais cliniques	3	2,5 millions de dollars
Consultation réglementaire	4	1,1 million de dollars

Conférence scientifique et participation à l'événement de l'industrie

Statistiques d'engagement des événements:

• Conférences scientifiques annuelles présentes: 12
• Présentations livrées: 8
• Interactions de réseautage: environ 250 professionnels
• Budget total de participation à l'événement: 450 000 $

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les dispositifs médicaux et les secteurs pharmaceutiques

Collplant Biotechnologies Ltd. maintient une équipe de vente directe spécialisée axée sur les dispositifs médicaux et les segments de marché pharmaceutique. Depuis 2024, l'équipe de vente de l'entreprise comprend 12 représentants professionnels.

Catégorie de canal de vente	Nombre de représentants	Couverture géographique
Secteur des dispositifs médicaux	7	États-Unis, Europe
Secteur pharmaceutique	5	États-Unis, Israël, Europe

Publications scientifiques et présentations de recherche

Collplant exploite les canaux de communication scientifiques pour diffuser les résultats de la recherche et les capacités de produit.

• Publications de journal évaluées par des pairs: 8 en 2023
• Présentations de la conférence de recherche: 15 conférences internationales
• Total des citations de recherche: 42 en 2023

Documentation technique en ligne et informations sur les produits

L'entreprise fournit des ressources numériques complètes pour les clients et partenaires potentiels.

Canal numérique	Visiteurs mensuels	Temps d'engagement moyen
Site Web de l'entreprise	3,500	4,2 minutes
Portail de documentation technique	1,200	6,7 minutes

Expositions et plateformes de réseautage de la conférence médicale

CollPlant participe activement aux conférences médicales et biotechnologiques pour présenter les innovations.

• Conférences assistées en 2023: 12
• Interactions totales des stands d'exposition: 287
• PARTAGNEMENTS POURRATS GÉNÉRÉS: 43

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: segments de clientèle

Laboratoires de recherche en médecine régénérative

Collplant cible les laboratoires de recherche en médecine régénérative avec sa technologie de bio-impression propriétaire et sa plate-forme de collagène humain recombinant.

Type de laboratoire de recherche	Taille du marché potentiel	Applications technologiques
Laboratoires de recherche universitaire	Marché de la recherche mondiale de la recherche en médecine régénérative de 2,3 milliards de dollars	Échafaudages de biopritage 3D
Instituts de recherche privés	Segment de génie tissulaire de 1,7 milliard de dollars	Biomatériaux à base de collagène

Les sociétés pharmaceutiques développant des thérapies avancées

CollPlant collabore avec les entreprises pharmaceutiques développant des solutions de médecine régénérative.

• Biomed Valley Discoveries Partnership for Breast Reconstruction
• Allergan esthétique collaboration pour les applications cutanées
• 4,5 milliards de dollars sur le marché mondial des produits médicinaux de thérapie avancée

Fabricants de dispositifs médicaux de guérison orthopédique et des plaies

Catégorie d'appareil	Valeur marchande	Intégration de la technologie Collplant
Implants orthopédiques	6,8 milliards de dollars sur le marché mondial	Échafaudages de régénération osseuse
Dispositifs de cicatrisation des plaies	Marché des soins des plaies de 3,2 milliards de dollars	Vins des plaies à base de collagène

Institutions de recherche académique et clinique

CollPlant fournit des biomatériaux avancés pour la recherche et le développement clinique.

• 12,7 milliards de dollars financement mondial de recherche universitaire
• Collaborations avec 17 institutions de recherche dans le monde
• Plateformes technologiques pour les études d'ingénierie tissulaire

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: Structure des coûts

Investissement important dans la recherche et le développement

Pour l'exercice 2023, Collplant Biotechnologies a déclaré des dépenses de R&D de 5,84 millions de dollars, représentant une composante critique de leur structure de coûts.

Année	Dépenses de R&D	Pourcentage des dépenses totales
2023	5,84 millions de dollars	42.3%
2022	4,92 millions de dollars	38.7%

Coûts de personnel élevés pour des experts en biotechnologie spécialisés

Les dépenses de personnel pour les professionnels spécialisés de la biotechnologie de Collplant ont totalisé 3,62 millions de dollars en 2023.

• Salaire moyen pour les chercheurs supérieurs en biotechnologie: 145 000 $
• Nombre total d'employés: 48
• Dépenses liées aux employés, y compris les avantages sociaux: 3,62 millions de dollars

Frais de fabrication et d'essais cliniques

Les coûts de fabrication et d'essai cliniques de Collplant pour 2023 s'élevaient à 7,21 millions de dollars.

Catégorie de dépenses	Coût
Coûts de fabrication	4,53 millions de dollars
Dépenses des essais cliniques	2,68 millions de dollars

Coûts de protection et de maintenance de la propriété intellectuelle

Collplant a investi 0,92 million de dollars dans la protection de la propriété intellectuelle en 2023.

• Coûts de dépôt de brevets et d'entretien: 0,62 million de dollars
• Frais juridiques pour la protection IP: 0,30 million de dollars

Structure totale des coûts pour 2023: 17,59 millions de dollars

Collplant Biotechnologies Ltd. (CLGN) - Modèle d'entreprise: Strots de revenus

Licensing Technologie de bio-impression propriétaire

CollPlant génère des revenus grâce à la licence de sa plate-forme de technologie bio-impression unique. En 2023, la société a signalé des accords de licence avec plusieurs partenaires stratégiques dans les secteurs de la médecine et des biomatériaux régénératifs.

Partenaire de licence	Zone technologique	Revenus estimés
United Therapeutics Corporation	Échafaudages pulmonaires à bioprint 3D	5,2 millions de dollars de paiement initial
Medtronic	Technologies de régénération des tissus	Frais de licence de 3,8 millions de dollars

Ventes de produits de médecine régénérative

Collplant génère des revenus directs grâce à la vente de ses produits de médecine régénérative, en particulier dans les soins des plaies et les applications orthopédiques.

• VerGenixfg Wound Care Product a généré 2,1 millions de dollars de ventes en 2023
• Les produits à base de collagène orthopédique ont réalisé 1,5 million de dollars de revenus

Collaborations de recherche et développement

La société obtient des revenus grâce à des partenariats stratégiques de recherche et développement avec des sociétés de dispositifs pharmaceutiques et médicaux.

Partenaire de collaboration	Focus de recherche	Valeur de collaboration
Allergan esthétique	Régénération des tissus dans l'esthétique	Financement de la recherche de 4,5 millions de dollars
CSL Behring	Ingénierie tissulaire avancée	Subvention collaborative de 3,7 millions de dollars

Paiements potentiels de jalons et de redevances

Les partenariats stratégiques de Collplant comprennent des structures potentielles de paiement des étapes et des redevances basées sur le développement de produits et les réalisations de commercialisation.

• United Therapeutics Partnership comprend des paiements de jalons potentiels jusqu'à 50 millions de dollars
• Les taux de redevances futurs estimés allant de 3 à 7% sur les ventes potentielles de produits

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Value Propositions

Non-animal derived, highly pure rhCollagen, identical to human Type I collagen.

• Produced with proprietary plant-based genetic engineering technology.
• Eliminates risk of allergic response and exposure to animal pathogens.

Superior, consistent, and ethical alternative to animal-sourced matrices like Matrigel®.

Comparison Metric	CollPlant Collink.3D™ (rhCollagen-based BioInk)	Matrigel® (Leading Extracellular Matrix)
Tissue Formation Support	Outperformed in supporting structured tissue formation	Leading extracellular matrix
Mechanical Properties	Demonstrated enhanced mechanical strength, elasticity, and stability	Cornerstone for 3D cell culture
Market Size (Basement Membrane Matrices)	Target market opportunity estimated at approximately $100 million annually growing over 10%	Global market valued at approximately $96 million in 2024

Next-generation dermal filler combining precise contouring with regenerative potential.

• Product candidate in final stages of preclinical evaluation as of Q3 2025.
• Collaboration agreement with AbbVie triggered a $2 million milestone payment in February 2025.
• Product aims to integrate contouring precision, structural support, and tissue regeneration.

BioInk platform for 3D bioprinting of tissues and organs.

• Collink.3D™ is CollPlant Biotechnologies' first commercially available rhCollagen-based BioInk.
• Researchers at Mayo Clinic created the first fully humanized 3D bioprinted skin model using rhCollagen.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center operational in late 2025.

Vergenix™ STR for promoting healing in tendinopathy and tissue repair.

Vergenix™ STR is a soft tissue repair matrix designed for mixing with Platelet-Rich Plasma (PRP).

Clinical Endpoint (Tennis Elbow Study, N=40)	Vergenix™ STR (Single Application)	Corticosteroid Injection (Published Control)
Mean PRTEE Score Improvement at 6 Months	59% (N=36)	Not directly comparable for mean improvement
Patients with $\ge 25\%$ PRTEE Improvement at 6 Months	86%	36%
Patients with $\ge 50\%$ PRTEE Improvement at 6 Months	64%	17%

Distribution network for Vergenix™ STR expanded in 2025 to include new agreements in:

• Poland.
• The Netherlands, Belgium, Luxembourg (Benelux).
• Spain, India, and Turkey.

Financial context for rhCollagen-based product sales:

• Nine months ended September 30, 2025 GAAP revenues: $2.3 million.
• Nine months ended September 30, 2024 GAAP revenues: $351,000.
• Q3 2025 GAAP revenues: $77,000, up from $4,000 in Q3 2024.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Relationships

You're looking at how CollPlant Biotechnologies Ltd. manages its key relationships as of late 2025. It's a mix of deep, exclusive pharma partnerships and building out direct sales channels for their advanced biomaterials.

Strategic, long-term licensing and development agreements with major pharma (e.g., AbbVie).

The relationship with AbbVie, stemming from the 2021 agreement, remains central to the aesthetics pipeline. CollPlant Biotechnologies Ltd. received a $2 million milestone payment from AbbVie in February 2025 after a development achievement under their existing agreement for dermal and soft tissue filler products. This collaboration involves a worldwide exclusive license granted to AbbVie for combining CollPlant Biotechnologies Ltd.'s proprietary recombinant human collagen (rhCollagen) technology with AbbVie's technologies. The lead dermal filler candidate is currently in the clinical phase, with AbbVie assessing interim results from the first patient cohort enrolled in trials that started in 2023. CollPlant Biotechnologies Ltd. plans to prioritize this collaboration into 2026. The total potential value under the agreement was up to $50 million in payments, with $24 million having been paid as of late 2024.

Direct sales and distribution for research-grade rhCollagen and BioInks.

Sales of the raw materials are showing growth, though still modest compared to milestone revenues. GAAP revenues for the nine months ended September 30, 2025, totaled $2.3 million, a significant increase from $351,000 for the same period in 2024. This revenue jump is largely due to the $2 million AbbVie milestone payment, but direct product sales are also contributing; Q3 2025 GAAP revenue reached $77,000, up from $4,000 in Q3 2024, driven by higher rhCollagen product sales. The market opportunity for the Collink.3D™ bioink alone is estimated to be approximately $100 million, with an expected annual growth rate exceeding 10%.

Here's a quick look at the revenue context for the direct product sales:

Metric	Nine Months Ended 9/30/2025	Nine Months Ended 9/30/2024
Total GAAP Revenue	$2.3 million	$351,000
Q3 GAAP Revenue	$77,000	$4,000

The company is actively working to scale this direct channel. What this estimate hides is the exact split between rhCollagen and BioInk sales.

Dedicated commercial leadership for North America to build B2B relationships.

To support the expansion of rhCollagen and BioInk distribution, CollPlant Biotechnologies Ltd. appointed a U.S.-based Head of Commercial Operations for North America in mid-2025. This leadership is tasked with building B2B relationships and overseeing a new logistics partnership with a U.S.-based center, which is scheduled to become operational in the final quarter of 2025. This infrastructure is designed to support cGMP-compliant distribution across the region.

Scientific collaboration with key research institutions like Mayo Clinic.

Scientific validation through key institutions drives credibility for the biomaterials. On October 16, 2025, CollPlant Biotechnologies Ltd. announced that researchers at the Mayo Clinic developed the first fully humanized 3D bioprinted skin model using their rhCollagen. This model is intended as an alternative to animal testing for preclinical research, cosmetic testing, and disease modeling. Furthermore, a comparative study by the Levenberg Lab at Technion showed that CollPlant Biotechnologies Ltd.'s rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation.

Key collaboration milestones include:

• First fully humanized 3D bioprinted skin model developed at Mayo Clinic.
• Publication in Archives of Dermatological Research in October 2025.
• Collink.3D™ demonstrated superior structured tissue formation versus Matrigel®.

High-touch support for medical device and biomanufacturing partners.

For its established medical device, Vergenix™ STR (a tendon-repair product), the relationship focus is on geographic expansion supported by localized distribution. The product is currently marketed primarily in Europe. In February 2025, CollPlant Biotechnologies Ltd. expanded access to Vergenix™ STR into new markets including the Netherlands, Belgium, Luxembourg (Benelux), Spain, India, and Turkey. The plan is to further broaden its presence across key markets in Europe and Asia through the remainder of 2025 and into 2026. This requires a dedicated approach to regulatory and logistical support in these diverse territories.

Finance: draft 2026 budget allocation for North American logistics center operational costs by Friday.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Channels

You're looking at how CollPlant Biotechnologies Ltd. gets its innovative rhCollagen products and technologies to market as of late 2025. It's a mix of high-level partnerships and direct regional sales efforts.

Global commercialization partner (AbbVie) for aesthetic products

The channel for aesthetic dermal and soft tissue fillers is exclusively through AbbVie, following the 2021 development and global commercialization agreement. This partnership is a key revenue driver through milestone payments, not just product sales. CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025 upon achieving a key development milestone for the dermal filler candidate. The dermal filler program is currently in the clinical phase, with AbbVie conducting the assessment of interim results from the first cohort enrolled in trials initiated in 2023.

Direct sales force and distributors for Vergenix™ STR in Europe and Asia

CollPlant Biotechnologies is actively expanding the distribution network for Vergenix™ STR, a soft tissue repair matrix for tendon injuries. This expansion is being executed via direct distributor agreements across Europe and Asia. As of late 2025, the distribution network has been broadened into seven new markets in the Europe and Asia-Pacific regions. Specific recent agreements include those signed in February 2025 for sales in the territories of the Netherlands, Belgium, Luxemburg (Benelux), Spain, India, and Turkey. Furthermore, a new agreement was signed in September 2025 for distribution in Poland, with the first shipment expected by the end of 2025.

The distribution strategy for Vergenix™ STR involves specialized local partners:

• Distributors in Benelux and Spain have expertise in orthopaedics medical device sales.
• Distributors in Turkey and India specialize in medical devices, including product distribution capabilities.
• The Polish distributor agreement was signed in Q3 2025.

New U.S.-based logistics center for North American raw material sales

For raw material sales of rhCollagen and BioInk in North America, CollPlant Biotechnologies is establishing a dedicated infrastructure. Expansion is expected through a new partnership with a U.S.-based logistics center, which is scheduled to become operational this quarter (Q4 2025, following Q3 reporting). This is being supported by a newly appointed, U.S.-based Head of Commercial Operations for North America. This channel targets the use of rhCollagen in advanced preclinical research and tissue engineering applications.

Licensing agreements for rhCollagen raw material to biomanufacturers

Beyond the AbbVie aesthetic license, the raw material platform itself is a channel through licensing and direct sales to biomanufacturers for research applications. The rhCollagen-based bioink, Collink.3D™, is being positioned as a raw material alternative. The market opportunity for consistent, animal-free biomaterials like Collink.3D™ is estimated at approximately $100 million-dollar market, with an estimated annual growth of over 10%.

The success of this raw material channel is being validated through key research collaborations:

Application/Study	Key Finding/Metric	Date/Context
Collink.3D™ vs. Matrigel®	Outperformed Matrigel® in supporting structured tissue formation.	Reported in Q3 2025.
Mayo Clinic Bioprinting	Used to create the first fully humanized 3D bioprinted skin model.	Reported in Q3 2025.

Scientific publications and conferences for research product awareness

Awareness for the rhCollagen platform, particularly for its use in non-animal testing alternatives, is driven by scientific validation. The findings from the Mayo Clinic and Technion studies serve as powerful awareness tools, demonstrating the platform's utility in creating alternatives to animal testing for preclinical research, drug discovery, and tissue modeling. These results are disseminated through scientific channels, effectively acting as a pull-through mechanism for raw material sales.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Segments

Global medical aesthetics companies seeking next-gen regenerative fillers.

• Exclusive license granted to AbbVie for dermal and soft tissue filler products based on proprietary rhCollagen technology.
• Received a $2 million milestone payment from AbbVie in February 2025.
• The photocurable dermal filler program is advancing toward the clinical stage following preclinical testing.

Pharmaceutical and cosmetic companies needing non-animal testing alternatives.

• The market opportunity for animal-free alternatives, such as Collink.3D™, is approximately $100 million-dollar market.
• This market is estimated to grow over 10% annually.
• Researchers at Mayo Clinic created the first fully humanized bioprinted skin model using rhCollagen as an alternative to animal testing for preclinical research.

Biotechnology and regenerative medicine researchers using 3D bioprinting.

• Successfully 3D bioprinted 200cc commercial-size regenerative breast implants.
• rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in a comparative study supporting structured tissue formation.
• Secured new patents in Japan for rhCollagen-based curable BioInks.

Orthopedic and sports medicine clinics utilizing Vergenix™ STR.

• Vergenix™ STR is marketed primarily in Europe and holds CE Mark approval.
• Expanded distribution in February 2025 to the Netherlands, Belgium, Luxembourg (Benelux), and Spain.
• Expanded distribution in 2025 to Turkey and India, with regulatory processes finalizing.
• Signed a new distribution agreement in Poland in September 2025.

Biomanufacturers requiring clinical-grade, scalable rhCollagen.

• GAAP revenues for the nine months ended September 30, 2025, were $2.3 million, with an increase mainly related to sales of rhCollagen-based products.
• GAAP revenues for the third quarter ended September 30, 2025, were $77,000, compared to $4,000 in Q3 2024, driven by rhCollagen product sales.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new logistics center.

Here's a quick look at the financial scale influencing these customer segments as of late 2025:

Metric	Amount (as of late 2025)
GAAP Revenue (Nine Months Ended Sep 30, 2025)	$2.3 million
GAAP Revenue (Trailing Twelve Months)	$2.48M
GAAP Revenue (Q3 2025)	$77,000
Cash Position (As of March 31, 2025)	$10.7 million
Net Proceeds from June 2025 Offering	$3.1 million
Q3 2025 Net Loss	$3.5 million
Current Market Cap	$28.23M

The company raised $3.1 million in net proceeds from a registered direct offering in June 2025.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Cost Structure

You're looking at the expenses CollPlant Biotechnologies Ltd. incurs to run its business, which centers on developing and commercializing its recombinant human Collagen (rhCollagen) platform. This cost structure reflects a heavy investment in R&D alongside the necessary overhead for a company scaling up commercial efforts, especially in North America.

Operating expenses are a key focus, showing the company's efforts to manage cash burn. For the third quarter ended September 30, 2025, GAAP operating expenses were reported at $3.3 million. This was an improvement, representing a decrease of approximately $1.0 million compared to the same period in 2024. On a non-GAAP basis, which excludes certain non-cash items, operating expenses for Q3 2025 were $3.0 million.

The cost structure is heavily influenced by research and development activities, which are critical for advancing the pipeline:

• High R&D expenses for clinical and preclinical programs, such as the dermal filler and the regenerative breast implant candidates, drive a significant portion of the spend.
• The cost reduction plan implemented by CollPlant Biotechnologies Ltd. specifically targeted R&D. The decrease in Q3 2025 operating expenses included a $519,000 reduction in research and development materials and subcontractors' expenses, largely related to the breast implants program.

Manufacturing and production costs for rhCollagen raw material and final products are embedded within the cost of revenues and operating expenses. While specific, current manufacturing cost breakdowns aren't explicitly detailed as a separate line item here, the focus on rhCollagen sales growth implies ongoing production costs. The company is also focused on expanding its North American distribution, which impacts SG&A and logistics costs.

Sales, General, and Administrative (SG&A) costs are also a major component, especially with the push for North American commercial expansion. The cost-cutting measures also hit personnel-related costs, which fall under SG&A and R&D overhead. Specifically, the Q3 2025 operating expense reduction included a $513,000 decrease in workforce expenses and share-based compensation expenses.

Intellectual property maintenance and legal fees are ongoing requirements for a biotech company protecting its platform technology. These costs are generally captured within the SG&A portion of the operating expenses.

Here's a look at the reported operating expense figures for the periods ending September 30, 2025:

Expense Metric	Period Ended September 30, 2025 Amount (USD)	Period Ended September 30, 2024 Amount (USD)
GAAP Operating Expenses (Q3)	$3.3 million	$4.3 million
Non-GAAP Operating Expenses (Q3)	$3.0 million	$3.8 million
GAAP Operating Expenses (Nine Months)	$10.0 million	$12.3 million
Non-GAAP Operating Expenses (Nine Months)	$9.0 million	$11.0 million

The company is actively managing these outflows. The nine-month GAAP operating expenses through September 30, 2025, totaled $10.0 million. This demonstrates a clear effort to manage the burn rate while advancing key programs.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Revenue Streams

You're looking at how CollPlant Biotechnologies Ltd. brings in cash as of late 2025. It's a mix of upfront payments from big partners and product sales, which is typical for a company at this stage in the regenerative space. Honestly, the milestone payments are the headline drivers right now.

The most concrete revenue source recently came from the strategic collaboration with AbbVie. Following a key development milestone, CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025, which was recorded in the first quarter of 2025 results. This payment relates to the development and commercialization agreement for dermal and soft tissue filler products using CollPlant's recombinant human collagen (rhCollagen) technology. That single event significantly boosted the top line early in the year.

Here's a quick look at how the revenue built up through the first nine months of 2025:

Period Ended	GAAP Revenue	Key Driver Mentioned
Q1 2025	$2.1 million	$2 million AbbVie milestone payment
Q3 2025	$77,000	Increase in sales of rhCollagen-based products
Nine Months Ended September 30, 2025	$2.3 million	Development milestone from AbbVie agreement

The nine-month 2025 GAAP revenue totaled $2.3 million, definitely a key metric for tracking progress against the prior year's nine-month revenue of $351,000 for the period ended September 30, 2024. That jump shows the impact of the AbbVie payment, but the smaller Q3 revenue suggests product sales are still ramping up.

Beyond the big partnership payments, CollPlant Biotechnologies Ltd. generates revenue from direct sales of its proprietary products. You need to track these streams as they represent the commercial viability of their platform technology:

• Sales of rhCollagen-based products, including the tendon-repair product, Vergenix™ STR. The company is actively expanding the international distribution network for Vergenix™ STR into new markets, including Europe and Asia.
• Sales of Collink.3D™ BioInk for research and bioprinting applications. CollPlant Biotechnologies announced the expansion of its BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance market presence. This bioink is used for things like creating tissue or organ-on-a-chip systems.

Licensing fees and royalties from commercial partners are an expected future stream, though current reports focus on expenses related to royalties. For instance, GAAP cost of revenues for the nine months ended September 30, 2025, included an increase in royalty expenses to the Israel Innovation Authority, mainly related to the $2 million milestone payment received from AbbVie in 2025. This shows that royalty obligations are tied to these upfront payments, with future commercial royalties yet to materialize significantly.

If onboarding takes 14+ days, churn risk rises, but for CollPlant Biotechnologies Ltd., the near-term focus is on converting the success of their bioink in comparative studies-like the one showing Collink.3D™ outperformed Matrigel® in structured tissue formation-into broader research sales. Finance: draft 13-week cash view by Friday.